Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.
Children
Coinfection
Mycoplasma pneumoniae
Pneumonia
Respiratory virus
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
30 May 2022
30 May 2022
Historique:
received:
26
02
2022
accepted:
25
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
The prevalence of refractory Mycoplasma pneumoniae (MP) pneumonia has been increasing. However, few studies have investigated the impact of respiratory virus coinfection in patients with MP pneumonia, and their results have been inconclusive. This study aimed to investigate the impact of respiratory virus coinfection in children hospitalized with MP pneumonia. This study enrolled 145 children hospitalized with MP pneumonia between May 2019 and March 2020. The patients were divided into two groups: the respiratory virus coinfection and non-coinfection groups. All the children underwent polymerase chain reaction testing for respiratory virus infection. Information on clinical, laboratory, and radiologic findings were obtained retrospectively via medical chart reviews. Children in the respiratory virus coinfection group were younger than those in the non-coinfection group. Respiratory virus coinfection in children hospitalized with MP pneumonia was significantly associated with persistence of fever more than 6 days (adjusted odds ratio [aOR], 2.394; 95% confidence interval [95% CI], 1.172-4.892), severe pneumonia (aOR, 4.602; 95% CI, 1.154-18.353), and poor response to the stepwise approach for MP pneumonia (aOR, 4.354; 95% CI, 1.374-13.800). In addition, higher levels of liver enzymes and lactate dehydrogenase at admission were associated with respiratory virus coinfection in children with MP pneumonia. The results of this study suggest that respiratory virus coinfection in children hospitalized with MP pneumonia may be associated with refractory MP pneumonia.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of refractory Mycoplasma pneumoniae (MP) pneumonia has been increasing. However, few studies have investigated the impact of respiratory virus coinfection in patients with MP pneumonia, and their results have been inconclusive. This study aimed to investigate the impact of respiratory virus coinfection in children hospitalized with MP pneumonia.
METHODS
METHODS
This study enrolled 145 children hospitalized with MP pneumonia between May 2019 and March 2020. The patients were divided into two groups: the respiratory virus coinfection and non-coinfection groups. All the children underwent polymerase chain reaction testing for respiratory virus infection. Information on clinical, laboratory, and radiologic findings were obtained retrospectively via medical chart reviews.
RESULTS
RESULTS
Children in the respiratory virus coinfection group were younger than those in the non-coinfection group. Respiratory virus coinfection in children hospitalized with MP pneumonia was significantly associated with persistence of fever more than 6 days (adjusted odds ratio [aOR], 2.394; 95% confidence interval [95% CI], 1.172-4.892), severe pneumonia (aOR, 4.602; 95% CI, 1.154-18.353), and poor response to the stepwise approach for MP pneumonia (aOR, 4.354; 95% CI, 1.374-13.800). In addition, higher levels of liver enzymes and lactate dehydrogenase at admission were associated with respiratory virus coinfection in children with MP pneumonia.
CONCLUSIONS
CONCLUSIONS
The results of this study suggest that respiratory virus coinfection in children hospitalized with MP pneumonia may be associated with refractory MP pneumonia.
Identifiants
pubmed: 35637540
doi: 10.1186/s12890-022-02005-y
pii: 10.1186/s12890-022-02005-y
pmc: PMC9150047
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Informations de copyright
© 2022. The Author(s).
Références
Radiology. 2000 Apr;215(1):184-8
pubmed: 10751485
Ann Dermatol Venereol. 2013 May;140(5):393-6
pubmed: 23663716
Emerg Infect Dis. 2021 Jun;27(6):1588-1597
pubmed: 34013867
Pediatr Gastroenterol Hepatol Nutr. 2016 Dec;19(4):243-250
pubmed: 28090469
BMC Infect Dis. 2020 Aug 26;20(1):633
pubmed: 32847534
Paediatr Respir Rev. 2010 Dec;11(4):233-9
pubmed: 21109182
Respir Care. 2015 Oct;60(10):1469-75
pubmed: 26060318
PLoS One. 2016 May 26;11(5):e0156465
pubmed: 27227519
BMC Pediatr. 2021 Feb 19;21(1):90
pubmed: 33607971
PLoS Med. 2013;10(5):e1001444
pubmed: 23690754
Clin Pediatr (Phila). 2018 Jan;57(1):57-61
pubmed: 28155329
Clin Microbiol Infect. 2020 Sep;26(9):1171-1177
pubmed: 32603802
PLoS One. 2020 Mar 17;15(3):e0230338
pubmed: 32182283
Pediatr Pulmonol. 2020 Apr;55(4):968-974
pubmed: 32040888
J Thorac Dis. 2018 Nov;10(11):6118-6127
pubmed: 30622783
BMC Infect Dis. 2020 Feb 12;20(1):132
pubmed: 32050912
Clin Diagn Lab Immunol. 2005 Oct;12(10):1246-50
pubmed: 16210492
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
BMC Pulm Med. 2019 Dec 18;19(1):251
pubmed: 31852460
Medicine (Baltimore). 2016 May;95(19):e3605
pubmed: 27175666
J Microbiol Immunol Infect. 2015 Feb;48(1):51-6
pubmed: 23927825
J Clin Med. 2021 Mar 10;10(6):
pubmed: 33801856
J Microbiol Immunol Infect. 2021 Aug;54(4):557-565
pubmed: 33268306
Front Microbiol. 2016 Jun 22;7:974
pubmed: 27446015
Scand J Infect Dis. 2009;41(6-7):515-9
pubmed: 19412880
Antimicrob Agents Chemother. 2006 Feb;50(2):709-12
pubmed: 16436730
J Clin Virol. 2018 Aug;105:77-83
pubmed: 29908521
Expert Rev Respir Med. 2019 May;13(5):481-488
pubmed: 30798629
Antimicrob Agents Chemother. 2013 Oct;57(10):5181-5
pubmed: 23896480
Pediatr Pulmonol. 2014 Jul;49(7):695-700
pubmed: 23861188
BMC Infect Dis. 2019 Oct 11;19(1):835
pubmed: 31601192
Sci Rep. 2017 Oct 11;7(1):12934
pubmed: 29021577
Pediatr Infect Dis J. 2000 Apr;19(4):293-8
pubmed: 10783017
Am J Infect Control. 2020 Oct;48(10):1231-1236
pubmed: 32113661